Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer’s Disease: A Phase I Clinical Trial
Journal of Alzheimer's Disease Reports · 01.11.2023 · 7 (1) · 1015-1024
DOI: 10.3233/adr-230012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease Reports, online erschienen am 07.09.2023. Verfasst von Brian A Willis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Work Completed While an Employee of Eli Lilly and Company. Current Affiliation: Eisai Inc., Nutley, NJ, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Demenz
Abstract (Originalsprache)
Background
Zagotenemab (LY3303560), a monoclonal antibody, preferentially binds to extracellular, misfolded, aggregated tau that has been implicated in Alzheimer’s disease (AD).
Objective
The goal of this study was to assess the safety and pharmacokinetics of multiple doses of zagotenemab in participants with AD.
Methods
This was a Phase Ib, multi-site, participant- and investigator-blind, placebo-controlled, parallel-group study in participants with mild cognitive impairment due to AD or mild to moderate AD. After screening, participants were randomized to zagotenemab 70 mg, 210 mg, or placebo every 4 weeks for up to 49 weeks and were followed up for 16 weeks.
Results
A total of 13 males and 9 females, aged 59 to 84 years, were dosed. No deaths occurred during this study. A total of 4 serious adverse events occurred in 2 participants who then discontinued the study. The most commonly reported (3 or more participants) treatment-emergent adverse events were sinus bradycardia, headache, fall, and bronchitis. The pharmacokinetics profile showed generally linear exposures across the dose range studied with a clearance of ~8 mL/h. The half-life of zagotenemab in serum was ~20 days. A dose-dependent increase in plasma tau was observed. No other significant pharmacodynamic differences were observed due to low dose levels and limited treatment duration.
Conclusions
No dose-limiting adverse events were observed with zagotenemab treatment. Pharmacokinetics of zagotenemab were typical for a monoclonal antibody. Meaningful pharmacodynamic differences were not observed. Clinicaltrials.gov: NCT03019536
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Work Completed While an Employee of Eli Lilly and Company. Current Affiliation: Eisai Inc., Nutley, NJ, USA.
- Work Completed While an Employee of Eli Lilly and Company.
- Work Completed While an Employee of Eli Lilly and Company. Current Affiliation: Indiana University School of Medicine, Indianapolis, IN, USA.
- Eli Lilly and Company, Indianapolis, IN, USA.
- Eli Lilly and Company, Bracknell, UK.
- Lilly Centre for Clinical Pharmacology, Singapore.
Zitieren
APA
Willis, B. A., Lo, A. C., Dage, J. L., Shcherbinin, S., Chinchen, L., Andersen, S. W., LaBell, E. S., Perahia, D. G. S., Hauck, P. M., & Lowe, S. L. (2023). Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer’s Disease: A Phase I Clinical Trial. Journal of Alzheimer's Disease Reports, 7(1), 1015-1024. https://doi.org/10.3233/adr-230012
Vancouver
Willis BA, Lo AC, Dage JL, Shcherbinin S, Chinchen L, Andersen SW, et al. Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer’s Disease: A Phase I Clinical Trial. Journal of Alzheimer's Disease Reports. 2023;7(1):1015-1024. doi:10.3233/adr-230012
BibTeX
@article{Willis2023,
author = {Willis, Brian A and Lo, Albert C and Dage, Jeffrey L and Shcherbinin, Sergey and Chinchen, Louise and Andersen, Scott W and LaBell, Elizabeth S and Perahia, David G S and Hauck, Paula M and Lowe, Stephen L},
title = {Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer’s Disease: A Phase I Clinical Trial},
journal = {Journal of Alzheimer's Disease Reports},
year = {2023},
volume = {7},
number = {1},
pages = {1015--1024},
doi = {10.3233/adr-230012}
}
EUVIMED